APOB and type 2 diabetes mellitus: A phase III trial in T2DM patients demonstrated significant reduction in fasting TG and ApoB48 by 45% and 56%, respectively, for 52 weeks in the group treated with pemafibrate, a more potent and selective PPARα agonist with minimal adverse effects [127].